MultiCell’s Majority Owned Subsidiary Acquires Bioabsorbable Interventional Cardiology Stent Assets
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal⢠BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank.  Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain …

Read more on PR Newswire via Yahoo! Finance

Leave a Reply

You must be logged in to post a comment. Login »

Enter your email address:

Delivered by FeedBurner



Related Posts









  • YOURLINK HERE
    BANNERLINKER
    CLASSIFIEDSPK
    COMPLETEB2B
    DOMAINSTRADE
    EBUSINESSPORT
    GARMENTSNETWORK
    GEMS22
    GULFVEHICLES
    INDIANCOMMERCIALS
    JOBS22
    KHURRUM
    OMANTRADERS
    PAKAUTOMOBILES
    PETROSCRAP
    PKBUSINESS
    PKGARMENTS
    SURPLUSOFFERS
    TOPDEALINGS
    TRADERS22
    UAECLASSIFIEDS
    UAECOMPUTERS
    UAEGARMENTS
    UAEMETALS
    UAEMOBILES
    UAEPLASTICS
    UAEPROPERTIES
    UAEPROPERTY
    UAEREALESTATE
    UAESTOCKLOTS
    UAETOPICS
    UAETRADERS
    UAEVEHICLES
    URLSUBMITS
    USACOMMERCIALS
    YOUNGDEALERS